On September 20, 2024, the Federal Trade Commission (“FTC”) filed an administrative complaint against Caremark Rx, Express Scripts and OptumRx, and their affiliated group purchasing organizations (“GPOs”), for engaging in anticompetitive and unfair rebate practices resulting in the artificial inflation of insulin prices. The FTC alleged that by creating a system in which drug manufacturers…Read More
Pressure on PBMs Intensifies as FTC Targets Top PBMs Over Insulin Rebates
Posted on September 30, 2024 in Health Law News
Published by: Hall Render